Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis
P P
PP
Athens University, Greece. psfikakis@med.uoa.gr
Markomichelakis
N
N
Alpsoy
E
E
Assaad-Khalil
S
S
Bodaghi
B
B
Gul
A
A
Ohno
S
S
Pipitone
N
N
Schirmer
M
M
Stanford
M
M
Wechsler
B
B
Zouboulis
C
C
Kaklamanis
P
P
Yazici
H
H
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000188:drug therapy*; D016903:Drug Monitoring / Q000379:methods; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D000069285:Infliximab; D018579:Patient Selection; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept